ChemoCentryx Inc. (CCXI) Drops 13.88% on January 06

Equities Staff |

ChemoCentryx Inc. (CCXI) was one of the Russell 2000's biggest losers for Wednesday January 06 as the stock slid 13.88% to $5.87, a loss of $-0.945 per share. Starting at an opening price of $6.49 a share, the stock traded between $5.84 and $6.91 over the course of the trading day. Volume was 446,644 shares over 2,130 trades, against an average daily volume of 153,925 shares and a total float of 44.13 million.

The losses send ChemoCentryx Inc. down to a market cap of $258.83 million. In the last year, ChemoCentryx Inc. has traded between $9.46 and $5.40, and its 50-day SMA is currently $7.25 and 200-day SMA is $7.41.

Chemocentryx Inc is a biopharmaceutical company engaged in discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer.

ChemoCentryx Inc. is based out of Mountain View, CA and has some 58 employees. Its CEO is Thomas J. Schall.

For a complete fundamental analysis analysis of ChemoCentryx Inc., check out’s Stock Valuation Analysis report for CCXI. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Propanc Health Group Corp

Propanc Health Group Corp is an early stage healthcare company. It is engaged in developing new cancer treatments for patients, suffering from pancreatic and colorectal cancer.

Private Markets

Ozobot by Evollve Inc

Ozobot is a world leader in compact super intelligent robots that entertain and educate through fun interactive gaming.


Airbnb is a community marketplace for people to list, discover, and book unique accommodations around the world — online or from a mobile phone. Whether an apartment for a night,…